Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

DGX vs UNH vs CVS vs VEEV

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
DGX
Quest Diagnostics Incorporated

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$21.12B
5Y Perf.+61.3%
UNH
UnitedHealth Group Incorporated

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$335.60B
5Y Perf.+21.3%
CVS
CVS Health Corporation

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$111.40B
5Y Perf.+33.2%
VEEV
Veeva Systems Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$27.35B
5Y Perf.-23.1%

DGX vs UNH vs CVS vs VEEV — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
DGX logoDGX
UNH logoUNH
CVS logoCVS
VEEV logoVEEV
IndustryMedical - Diagnostics & ResearchMedical - Healthcare PlansMedical - Healthcare PlansMedical - Healthcare Information Services
Market Cap$21.12B$335.60B$111.40B$27.35B
Revenue (TTM)$11.28B$449.71B$407.90B$3.20B
Net Income (TTM)$1.02B$12.04B$2.93B$909M
Gross Margin33.2%18.8%13.9%75.5%
Operating Margin14.3%4.2%1.5%28.7%
Forward P/E17.8x20.2x12.2x19.0x
Total Debt$6.92B$78.39B$93.59B$96M
Cash & Equiv.$420M$24.36B$8.51B$1.42B

DGX vs UNH vs CVS vs VEEVLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

DGX
UNH
CVS
VEEV
StockMay 20May 26Return
Quest Diagnostics I… (DGX)100161.3+61.3%
UnitedHealth Group … (UNH)100121.3+21.3%
CVS Health Corporat… (CVS)100133.2+33.2%
Veeva Systems Inc. (VEEV)10076.9-23.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: DGX vs UNH vs CVS vs VEEV

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CVS and VEEV are tied at the top with 3 categories each — the right choice depends on your priorities. Veeva Systems Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. UNH also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
DGX
Quest Diagnostics Incorporated
The Long-Run Compounder

DGX is the clearest fit if your priority is long-term compounding and sleep-well-at-night.

  • 181.3% 10Y total return vs VEEV's 5.2%
  • Lower volatility, beta 0.07, Low D/E 95.0%, current ratio 1.04x
Best for: long-term compounding and sleep-well-at-night
UNH
UnitedHealth Group Incorporated
The Insurance Pick

UNH is the clearest fit if your priority is dividends.

  • 2.4% yield, 25-year raise streak, vs CVS's 3.1%, (1 stock pays no dividend)
Best for: dividends
CVS
CVS Health Corporation
The Insurance Pick

CVS carries the broadest edge in this set and is the clearest fit for income & stability and defensive.

  • Dividend streak 0 yrs, beta 0.05, yield 3.1%
  • Beta 0.05, yield 3.1%, current ratio 0.84x
  • Lower P/E (12.2x vs 19.0x)
  • Beta 0.05 vs VEEV's 0.77
Best for: income & stability and defensive
VEEV
Veeva Systems Inc.
The Growth Play

VEEV is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 16.3%, EPS growth 25.9%, 3Y rev CAGR 14.0%
  • 16.3% revenue growth vs CVS's 7.8%
  • 28.4% margin vs CVS's 0.7%
  • 11.1% ROA vs CVS's 1.1%, ROIC 12.9% vs 5.0%
Best for: growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthVEEV logoVEEV16.3% revenue growth vs CVS's 7.8%
ValueCVS logoCVSLower P/E (12.2x vs 19.0x)
Quality / MarginsVEEV logoVEEV28.4% margin vs CVS's 0.7%
Stability / SafetyCVS logoCVSBeta 0.05 vs VEEV's 0.77
DividendsUNH logoUNH2.4% yield, 25-year raise streak, vs CVS's 3.1%, (1 stock pays no dividend)
Momentum (1Y)CVS logoCVS+34.7% vs VEEV's -29.4%
Efficiency (ROA)VEEV logoVEEV11.1% ROA vs CVS's 1.1%, ROIC 12.9% vs 5.0%

DGX vs UNH vs CVS vs VEEV — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

DGXQuest Diagnostics Incorporated
FY 2025
Diagnostic Information Services Business
100.0%$10.8B
UNHUnitedHealth Group Incorporated
FY 2025
Unitedhealthcare
94.4%$332.4B
Optumhealth
5.6%$19.8B
CVSCVS Health Corporation
FY 2025
Pharmacy Revenue
58.9%$229.0B
Premiums
34.6%$134.8B
Front Store Revenue
5.5%$21.5B
Product and Service, Other
1.0%$3.9B
VEEVVeeva Systems Inc.
FY 2025
Subscription Services Veeva Research And Development
43.0%$1.2B
Subscription Services Veeva Commercial Cloud
40.2%$1.1B
Professional Services Veeva Research And Development
10.1%$277M
Professional Services Veeva Commercial Cloud
6.7%$185M

DGX vs UNH vs CVS vs VEEV — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLCVSLAGGINGUNH

Income & Cash Flow (Last 12 Months)

VEEV leads this category, winning 5 of 6 comparable metrics.

UNH is the larger business by revenue, generating $449.7B annually — 140.7x VEEV's $3.2B. VEEV is the more profitable business, keeping 28.4% of every revenue dollar as net income compared to CVS's 0.7%. On growth, VEEV holds the edge at +16.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricDGX logoDGXQuest Diagnostics…UNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…VEEV logoVEEVVeeva Systems Inc.
RevenueTrailing 12 months$11.3B$449.7B$407.9B$3.2B
EBITDAEarnings before interest/tax$1.9B$23.2B$10.5B$956M
Net IncomeAfter-tax profit$1.0B$12.0B$2.9B$909M
Free Cash FlowCash after capex$1.3B$19.7B$7.4B$1.4B
Gross MarginGross profit ÷ Revenue+33.2%+18.8%+13.9%+75.5%
Operating MarginEBIT ÷ Revenue+14.3%+4.2%+1.5%+28.7%
Net MarginNet income ÷ Revenue+9.1%+2.7%+0.7%+28.4%
FCF MarginFCF ÷ Revenue+11.8%+4.4%+1.8%+43.7%
Rev. Growth (YoY)Latest quarter vs prior year+9.2%+2.0%+6.2%+16.0%
EPS Growth (YoY)Latest quarter vs prior year+15.5%+0.7%+63.1%+23.9%
VEEV leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

CVS leads this category, winning 4 of 6 comparable metrics.

At 21.8x trailing earnings, DGX trades at a 65% valuation discount to CVS's 62.8x P/E. On an enterprise value basis, DGX's 12.7x EV/EBITDA is more attractive than VEEV's 28.4x.

MetricDGX logoDGXQuest Diagnostics…UNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…VEEV logoVEEVVeeva Systems Inc.
Market CapShares × price$21.1B$335.6B$111.4B$27.4B
Enterprise ValueMkt cap + debt − cash$27.6B$389.6B$196.5B$26.0B
Trailing P/EPrice ÷ TTM EPS21.81x27.95x62.81x30.92x
Forward P/EPrice ÷ next-FY EPS est.17.77x20.19x12.19x18.98x
PEG RatioP/E ÷ EPS growth rate1.70x
EV / EBITDAEnterprise value multiple12.71x16.70x13.11x28.40x
Price / SalesMarket cap ÷ Revenue1.91x0.75x0.28x8.56x
Price / BookPrice ÷ Book value/share2.96x3.31x1.47x3.89x
Price / FCFMarket cap ÷ FCF15.54x20.88x14.27x19.33x
CVS leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

VEEV leads this category, winning 6 of 9 comparable metrics.

DGX delivers a 13.8% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $4 for CVS. VEEV carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to CVS's 1.24x. On the Piotroski fundamental quality scale (0–9), DGX scores 7/9 vs CVS's 5/9, reflecting strong financial health.

MetricDGX logoDGXQuest Diagnostics…UNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…VEEV logoVEEVVeeva Systems Inc.
ROE (TTM)Return on equity+13.8%+11.5%+3.9%+13.4%
ROA (TTM)Return on assets+6.3%+3.9%+1.1%+11.1%
ROICReturn on invested capital+8.8%+9.2%+5.0%+12.9%
ROCEReturn on capital employed+11.5%+9.7%+6.1%+13.8%
Piotroski ScoreFundamental quality 0–97656
Debt / EquityFinancial leverage0.95x0.77x1.24x0.01x
Net DebtTotal debt minus cash$6.5B$54.0B$85.1B-$1.3B
Cash & Equiv.Liquid assets$420M$24.4B$8.5B$1.4B
Total DebtShort + long-term debt$6.9B$78.4B$93.6B$96M
Interest CoverageEBIT ÷ Interest expense6.26x4.71x2.11x
VEEV leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

DGX leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in DGX five years ago would be worth $14,771 today (with dividends reinvested), compared to $6,471 for VEEV. Over the past 12 months, CVS leads with a +34.7% total return vs VEEV's -29.4%. The 3-year compound annual growth rate (CAGR) favors DGX at 14.1% vs UNH's -7.1% — a key indicator of consistent wealth creation.

MetricDGX logoDGXQuest Diagnostics…UNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…VEEV logoVEEVVeeva Systems Inc.
YTD ReturnYear-to-date+10.8%+10.6%+10.6%-23.4%
1-Year ReturnPast 12 months+9.9%-3.2%+34.7%-29.4%
3-Year ReturnCumulative with dividends+48.5%-19.9%+36.6%-5.2%
5-Year ReturnCumulative with dividends+47.7%-2.6%+17.0%-35.3%
10-Year ReturnCumulative with dividends+181.3%+220.6%+3.5%+519.4%
CAGR (3Y)Annualised 3-year return+14.1%-7.1%+11.0%-1.8%
DGX leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

CVS leads this category, winning 2 of 2 comparable metrics.

CVS is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than VEEV's 0.77 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs VEEV's 54.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricDGX logoDGXQuest Diagnostics…UNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…VEEV logoVEEVVeeva Systems Inc.
Beta (5Y)Sensitivity to S&P 5000.07x0.59x0.05x0.77x
52-Week HighHighest price in past year$213.50$395.52$88.63$310.50
52-Week LowLowest price in past year$164.65$234.60$58.35$148.05
% of 52W HighCurrent price vs 52-week peak+89.4%+93.5%+98.5%+54.2%
RSI (14)Momentum oscillator 0–10040.175.969.349.6
Avg Volume (50D)Average daily shares traded841K7.9M7.4M2.3M
CVS leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.

Analyst consensus: DGX as "Hold", UNH as "Buy", CVS as "Buy", VEEV as "Buy". Consensus price targets imply 66.5% upside for VEEV (target: $280) vs 4.2% for UNH (target: $385). For income investors, CVS offers the higher dividend yield at 3.06% vs DGX's 1.64%.

MetricDGX logoDGXQuest Diagnostics…UNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…VEEV logoVEEVVeeva Systems Inc.
Analyst RatingConsensus buy/hold/sellHoldBuyBuyBuy
Price TargetConsensus 12-month target$220.57$385.43$95.20$280.10
# AnalystsCovering analysts34524142
Dividend YieldAnnual dividend ÷ price+1.6%+2.4%+3.1%
Dividend StreakConsecutive years of raises15250
Dividend / ShareAnnual DPS$3.12$8.70$2.67
Buyback YieldShare repurchases ÷ mkt cap+2.1%+1.7%0.0%+0.6%
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.
Key Takeaway

VEEV leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CVS leads in 2 (Valuation Metrics, Risk & Volatility). 1 tied.

Best OverallCVS Health Corporation (CVS)Leads 2 of 6 categories
Loading custom metrics...

DGX vs UNH vs CVS vs VEEV: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is DGX or UNH or CVS or VEEV a better buy right now?

For growth investors, Veeva Systems Inc.

(VEEV) is the stronger pick with 16. 3% revenue growth year-over-year, versus 7. 8% for CVS Health Corporation (CVS). Quest Diagnostics Incorporated (DGX) offers the better valuation at 21. 8x trailing P/E (17. 8x forward), making it the more compelling value choice. Analysts rate UnitedHealth Group Incorporated (UNH) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — DGX or UNH or CVS or VEEV?

On trailing P/E, Quest Diagnostics Incorporated (DGX) is the cheapest at 21.

8x versus CVS Health Corporation at 62. 8x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 2x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — DGX or UNH or CVS or VEEV?

Over the past 5 years, Quest Diagnostics Incorporated (DGX) delivered a total return of +47.

7%, compared to -35. 3% for Veeva Systems Inc. (VEEV). Over 10 years, the gap is even starker: VEEV returned +519. 4% versus CVS's +3. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — DGX or UNH or CVS or VEEV?

By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.

05β versus Veeva Systems Inc. 's 0. 77β — meaning VEEV is approximately 1430% more volatile than CVS relative to the S&P 500. On balance sheet safety, Veeva Systems Inc. (VEEV) carries a lower debt/equity ratio of 1% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — DGX or UNH or CVS or VEEV?

By revenue growth (latest reported year), Veeva Systems Inc.

(VEEV) is pulling ahead at 16. 3% versus 7. 8% for CVS Health Corporation (CVS). On earnings-per-share growth, the picture is similar: Veeva Systems Inc. grew EPS 25. 9% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, VEEV leads at 14. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — DGX or UNH or CVS or VEEV?

Veeva Systems Inc.

(VEEV) is the more profitable company, earning 28. 4% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VEEV leads at 28. 7% versus 2. 6% for CVS. At the gross margin level — before operating expenses — VEEV leads at 75. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is DGX or UNH or CVS or VEEV more undervalued right now?

On forward earnings alone, CVS Health Corporation (CVS) trades at 12.

2x forward P/E versus 20. 2x for UnitedHealth Group Incorporated — 8. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VEEV: 66. 5% to $280. 10.

08

Which pays a better dividend — DGX or UNH or CVS or VEEV?

In this comparison, CVS (3.

1% yield), UNH (2. 4% yield), DGX (1. 6% yield) pay a dividend. VEEV does not pay a meaningful dividend and should not be held primarily for income.

09

Is DGX or UNH or CVS or VEEV better for a retirement portfolio?

For long-horizon retirement investors, Quest Diagnostics Incorporated (DGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

07), 1. 6% yield, +181. 3% 10Y return). Both have compounded well over 10 years (DGX: +181. 3%, VEEV: +519. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between DGX and UNH and CVS and VEEV?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DGX is a mid-cap quality compounder stock; UNH is a large-cap quality compounder stock; CVS is a mid-cap income-oriented stock; VEEV is a mid-cap high-growth stock. DGX, UNH, CVS pay a dividend while VEEV does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

DGX

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Stocks Like

UNH

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Dividend Yield > 0.9%
Run This Screen
Stocks Like

CVS

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 1.2%
Run This Screen
Stocks Like

VEEV

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 17%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform DGX and UNH and CVS and VEEV on the metrics below

Revenue Growth>
%
(DGX: 9.2% · UNH: 2.0%)
Net Margin>
%
(DGX: 9.1% · UNH: 2.7%)
P/E Ratio<
x
(DGX: 21.8x · UNH: 27.9x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.